Novo traded 4% lower on the news Friday. Diabetes drug Ozempic and weight-loss drug Wegovy top the list, along with a number of others like Merck's (MRK) diabetes drug Janumet. "The Biden-Harris ...

Abra caminho para o novo com 4 simpatias para conquistar um novo amor. Primeiramente, escreva em um pedaço de tecido branco as características do amor que deseja atrair. Depois disso ...

Como deve saber, o novo iPhone SE 4 (ou iPhone 16E) deve chegar ao mercado algures em Abril de 2025, de forma a bater o pé a todos os gama média de nova geração do mundo Android, e de facto ...

Lançado no mercado japonês há menos de uma semana, o Suzuki Jimny de quatro portas – localmente chamado de Nomad – já pode ser considerado um verdadeiro sucesso de vendas. Em apenas quatro dias de ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

That is when a new study of the drug is also planned — details were shared in Novo's earnings presentation, released today, and Redefine 4 study results have been promised for H225. Novo stock ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

Despite the company’s enthusiasm, questions remain about how Novo's latest numbers can move the needle in a competitive market. The company's stock price decline of 4% on Friday seems to ...

Novo Nordisk closed up 4.5% Wednesday. Shares of obesity drug rival Eli Lilly, meanwhile, rose 1.4%. Speaking to CNBC Wednesday, CEO and President Lars Fruergaard Jørgensen said that the company ...

LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk (NVO) forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors ...